Why is testing so hard?

Symptoms of Bundibugyo overlap with those of malaria, typhoid fever, and other far more common illnesses. A clinical exam alone cannot confirm Bundibugyo infection. Definitive diagnosis requires laboratory testing.

In parts of the DRC, lab capacity is limited and samples may travel long distances to reach a national reference laboratory. Sullivan wrote that "delays in specimen collection, transportation and testing can postpone confirmation by days or weeks, which hinders the isolation of infected persons, contact tracing and the initiation of outbreak-control measures."

Those delays matter during any hemorrhagic-fever outbreak. Quick case-finding lets responders separate infected patients from healthy people and trace contacts before transmission chains widen. The same testing delay also postpones public communication that helps communities recognize the threat.

Is there a vaccine or treatment?

No licensed vaccine or therapeutic exists specifically for Bundibugyo. Scientists have made considerable progress on countermeasures for Ebola, Sudan virus, and Marburg virus — three other filoviruses with larger outbreak histories.

Early data suggest vaccines designed against related filoviruses might offer some cross-protection against Bundibugyo. But the pathogen remains an example of a dangerous virus for which tailored medical tools are still limited. Treatment of current patients relies on supportive care, since no virus-specific drug exists.

What does this say about outbreak preparedness?

Sullivan's argument extends well beyond Bundibugyo. Decades of low activity do not guarantee future safety, she notes. Predicting which pathogen will drive the next major emergency remains difficult. The current outbreak shows that rare viruses can return at any time.

She calls for medical countermeasures aimed more broadly at viruses capable of causing severe human illness, not only at the pathogens that already draw the most funding and attention. Preparedness also needs more than diagnostics and shots. Health systems must coordinate quickly when an outbreak crosses borders.

"Preparedness planning should extend beyond diagnostics, vaccines, and therapeutics to include operational readiness for multinational outbreak response," Sullivan said.

What are the limits of this review?

The NEJM article is a synthesis of clinical and public-health evidence, not a new clinical trial or fresh epidemiological study. Case counts depend on testing capacity, so the 695 confirmed cases almost certainly understate infections in areas where sick people never reach a clinic or sample collection sites.

Sullivan's call for expanded countermeasure development is a recommendation, not yet adopted policy. Vaccine pipelines for rarer filoviruses remain underfunded relative to those for the headline pathogens.